Literature DB >> 12373466

Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge.

Luca Gabutti1, Claudio Marone, Giuseppe Colucci, Francesca Duchini, Carlo Schönholzer.   

Abstract

OBJECTIVE: Feasibility and safety evaluation of regional citrate anticoagulation (RCA) versus systemic heparinization for continuous venovenous hemodiafiltration. DESIGN AND
SETTING: Combined retrospective and prospective observational study performed in a secondary multidisciplinary intensive care unit of the Ospedale Civico Lugano Switzerland. PATIENTS AND
INTERVENTIONS: Twelve hemodynamically unstable patients (median APACHE II score 26, interquartile range 22-29) in whom heparin was judged to be at least temporarily contraindicated. A switch from RCA (predilution setting; same iso-osmotic replacement and dialysis fluid) to heparinization or vice versa was recommended for the final evaluation; 56 dialyzers were used for RCA (1,400 h) and 39 for heparinization (1,271 h). MEASUREMENTS AND
RESULTS: Median dialyzer life span was 24.2 h (interquartile range 17.4-42.3) for RCA and 42.5 h (20.6-69.1) for heparinization. Fluid control and dialysis quality were similar in the two groups and required no additional intervention. The risk of significant hypocalcemia and metabolic alkalosis was higher at the beginning of the RCA program and decreased with the further training of the staff. Seven bleeding episodes occurred with heparinization vs. three in RCA.
CONCLUSIONS: RCA may be a safe and useful form of anticoagulation which is more expensive than heparinization but helps to minimize bleeding risk. The risk of metabolic complications is higher at the beginning of a new RCA program. For centers lacking experienced staff we suggest reserving this technique for patients with rapid clotting of the extracorporeal circuit if treated without anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373466     DOI: 10.1007/s00134-002-1443-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  20 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  [Citrate anticoagulation in acute renal replacement therapy : Method of choice].

Authors:  R D Frank
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-22       Impact factor: 0.840

3.  Regional citrate anticoagulation for pediatric CRRT using integrated citrate software and physiological sodium concentration solutions.

Authors:  Jean-Michel Liet; Emma Allain-Launay; Bénédicte Gaillard-LeRoux; François Barrière; Alexis Chenouard; Jean-Marc Dejode; Nicolas Joram
Journal:  Pediatr Nephrol       Date:  2014-02-15       Impact factor: 3.714

4.  Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.

Authors:  Mehran Monchi; Denis Berghmans; Didier Ledoux; Jean-Luc Canivet; Bernard Dubois; Pierre Damas
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

5.  Citrate anticoagulation for continuous renal replacement therapy in critically ill patients: success and limits.

Authors:  Filippo Mariano; Daniela Bergamo; Ezio Nicola Gangemi; Zsuzsanna Hollo'; Maurizio Stella; Giorgio Triolo
Journal:  Int J Nephrol       Date:  2011-03-16

Review 6.  Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?

Authors:  Raymond Vanholder; Wim Van Biesen; Eric Hoste; Norbert Lameire
Journal:  Crit Care       Date:  2011-01-28       Impact factor: 9.097

7.  Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.

Authors:  Shaikh A Nurmohamed; Borefore P Jallah; Marc G Vervloet; Gul Yldirim; Pieter M ter Wee; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2013-04-18       Impact factor: 2.388

8.  Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.

Authors:  Heleen M Oudemans-van Straaten; Marlies Ostermann
Journal:  Crit Care       Date:  2012-12-07       Impact factor: 9.097

9.  Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes.

Authors:  Luca Gabutti; Barbara Lucchini; Claudio Marone; Lorenzo Alberio; Michel Burnier
Journal:  BMC Nephrol       Date:  2009-03-05       Impact factor: 2.388

10.  Haemodynamic consequences of changing bicarbonate and calcium concentrations in haemodialysis fluids.

Authors:  Luca Gabutti; Giorgia Bianchi; Davide Soldini; Claudio Marone; Michel Burnier
Journal:  Nephrol Dial Transplant       Date:  2008-10-08       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.